Loading...
Antiretroviral therapy is strongly recommended for HIV-infected pregnant women because of its demonstrated efficacy in maintaining maternal health and in reducing the risk for vertical transmission. Lopinavir/ritonavir is the preferred protease inhibitor (PI) for pregnant women, but recommendations regarding optimal dosing of the tablet formulation in pregnancy are not provided in current guidelines. Results from a pharmacokinetic study, involving 33 HIV-infected pregnant women, may help with proper dose selection.
The women received standard lopinavir/r dosing during the second trimester (two tablets — 400 mg lopinavir/100 mg ritonavir — twice daily), a higher dose during the third trimester (three tablets — 600 mg lopinavir/150 mg ritonavi…